Dueling Fools: Elan Bull Rebuttal
Motley Fool - USA
He thinks multiple sclerosis drug Tysabri is too risky and not profitable enough to support the current valuation, but I'm convinced otherwise for a couple ...
See all stories on this topic

Wonder Drug To Be Blocked
Sky News - Isleworth,UK
Tysabri is a monoclonal antibody that has also proven to be beneficial in treating Crohn's disease, which, like MS, is also an autoimmune disorder. ...
See all stories on this topic

PDL's Friend Comes Through
Motley Fool - USA
Biogen and partner Elan (NYSE: ELN) learned that two years ago, with Tysabri running into trouble in combination therapy. Just as PDL deserves blame for its ...
See all stories on this topic

Dueling Fools: Elan Bull
Motley Fool - USA
You may have heard of this promising little drug called Tysabri. Clinical trials and nearly a year of real-world sales and treatments have so far agreed ...
See all stories on this topic

Dueling Fools: Elan Bear
Motley Fool - USA
Elan is best known nowadays for its multiple sclerosis treatment Tysabri and the saga of bringing it to market. Elan and marketing partner Biogen IDEC ...
See all stories on this topic